Istiratumab

Drug Profile

Istiratumab

Alternative Names: MM-141

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adimab
  • Developer Adimab; Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Ovarian cancer

Most Recent Events

  • 31 Aug 2017 Merrimack Pharmaceuticals terminates a phase I trial due to sponsor decision in Solid tumours (Late-stage disease, Combination therapy) in USA (Parenteral) (NCT02538627)
  • 09 Aug 2017 Merrimack completes enrolment in the phase II CARRIE trial in Pancreatic cancer
  • 19 Jun 2017 Merrimack Pharmaceuticals completes enrolment in the phase II CARRIE trial for Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy) in USA, Spain, Canada, Germany, Poland and United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top